

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

1. A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a polynucleotide encoding a CD4 receptor.
2. A pharmaceutical composition according to claim 1 wherein (i) and (ii) are encoded on separate vectors.
3. A pharmaceutical composition according to claim 1 wherein (i) and (ii) are encoded on the same vector.
4. A pharmaceutical composition according to claim 1 wherein said HIV envelope protein and said CD4 receptor are expressed as separate proteins.
5. A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a CD4 receptor.
6. A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is expressed as part of a fusion protein and/or the CD4 receptor is expressed as part of a fusion protein.
7. A pharmaceutical composition according to claim 1 wherein the CD4 receptor is soluble CD4 receptor.
8. A pharmaceutical composition according to claim 1 wherein the CD4 receptor is human CD4 receptor.
9. A pharmaceutical composition according to claim 1 wherein the CD4 receptor is a CD4 surrogate molecule.
10. A pharmaceutical composition according to claim 1 wherein the CD4 receptor is a CD4 surrogate molecule which is M33 mini-protein.

11. A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is HIV-1 envelope protein.
12. A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is CCR5-dependent HIV envelope protein.
13. A pharmaceutical composition according to claim 1 wherein the polynucleotide encoding the HIV envelope protein encodes gpl60.
14. A pharmaceutical composition according to claim 1 further comprising a pharmaceutically acceptable diluent or excipient.
15. A pharmaceutical composition according to claim 1 for use in the treatment of HIV.
16. A pharmaceutical composition according to claim 1 in the form of a vaccine.
17. A method of treating or preventing HIV infection which method comprises administering to a subject a pharmaceutical composition as defined in claim 1.
18. A fixed cell wherein said cell expresses an HIV envelope protein and further wherein said envelope protein is complexed with a CD4 receptor.
19. A method of treating or preventing HIV infection which method comprises administering to a subject a fixed cell as defined in claim 18.
20. A method of treating or preventing a disease or condition of, or related to, the immune system which method comprises administering to a fixed cell as defined in claim 18.
21. A vaccine comprising the fixed cell as defined in claim 20.
22. Use of a fixed cell as defined in claim 20 for the preparation of a medicament for use in

generating anti-HIV monoclonal antibodies.

23. An antibody immunospecific for the fixed cell as defined in claim 20.
24. A method of treating or preventing HIV infection which method comprises administering to a subject an antibody as defined in claim 23.
25. A method of treating or preventing a disease or condition of, or related to, the immune system which method comprises administering to a subject an antibody as defined in claim 23.
26. A hybridoma cell line having the identifying characteristics of the cell line deposited with the Advanced Biotechnology Center Inter Lab Cell Line Collection (CBA ICLB) wherein said hybridoma produces DB-81.
27. An antibody molecule produced by the hybridoma of claim 26.
28. An antibody that specifically binds the same idiotope as the antibody produced by the hybridoma of claim 26.
29. A method of generating a fixed cell according to claim 18 comprising
  - (i) expressing HIV envelope protein on the surface of living cells;
  - (ii) complexing the envelope protein of(i) with a CD4 receptor; and
  - (iii) fixing the CD4 coated cells.
30. A pharmaceutical composition comprising a fixed cell according to claim 23 and a pharmaceutically acceptable diluent or excipient.
31. A pharmaceutical composition comprising a population of fixed cells according to claim 23, wherein within the population more than one HIV envelope serotype is expressed, and a pharmaceutically acceptable diluent or excipient.